罗格列酮对糖耐量受损人群C反应蛋白和纤维蛋白原的影响

The effect and their significance of rosiglitazone on serum CRP and Fg in subjects with impaired glucose tolerance

目的观察罗格列酮干预治疗对糖耐量受损(IGT)人群血浆超敏C-反应蛋白(hsCRP)和纤维蛋白原(Fg)水平的影响及与胰岛素抵抗的关系。方法60例IGT受试者被随机分为治疗组(饮食+运动+罗格列酮,n=30)及对照组(单纯饮食+运动,n=30),分别在治疗前和12周后检测hsCRP、Fg、血糖,血脂(TG、TC、LDL-C、HDL-C)和胰岛素水平,并测量其身高、体重和血压。结果(1)与基础比较,治疗组12周后,hsCRP、Fg、胰岛素抵抗指数(HOMA-IR)及血压、血糖、TG、TC、LDL-C水平下降,HDL-C水平升高,P<0.05,对照组上述各指标的轻度变化,但无明显统计学差异;(2)相关分析显示,hsCRP及Fg与Homa-IR和空腹胰岛素水平的变化呈正相关。结论罗格列酮干预治疗在改善IGT患者胰岛素抵抗和糖脂代谢的同时,可减轻机体的低度炎症状态。

Objective To investigate the changes of plasma C-reaction protein（CRP）,fibrinogen（Fg） and their significance in subjects with impaired glucose tolerance after the treatment with rosiglitazone. Methods 60 subjects with IGT were divided into two groups：the control group（diet and excise） and treatment group（diet and excise with rosiglitazone 4mg daily ）.before and after treating for 12 weeks, plasma hsCRP, Fg, blood lipid and fasting insulin were measured, height, weight, waist and hip circumference and blood pressure also were recorded, then Homa-IR, BMI and WHR were calculated. Results （1） Rosiglitazone resulted in a significant reduction in CRP, Fg and HOMA-IR SBP, DBP, TG and LDL-C after the 12 weeks（ P 〈 0.05） ;In the rosiglitazone-treated group, reductions in hsCRP and Fg were significantly positive relationship with the changes of Homa-IR and serum fasting insulin. Conclusion Rosiglitazone significantly reduces the level of plasma CRP and Fg and improve insulin resistance.